Publications by authors named "P S BERGMAN"
Article Synopsis
- The human peptide LL-37 can trigger autophagy in macrophages, but its effectiveness varies based on post-translational modifications (PTMs) and its cellular source.
- Neutrophil-derived LL-37 was modified and did not induce autophagy, while macrophage-derived LL-37, mostly native, was effective in initiating this process.
- The presence of an intact N-terminal di-leucine motif in LL-37 is essential for autophagy activation, highlighting how modifications can influence its role in infection and inflammation.
Patients with hematologic malignancies (HM) are highly susceptible to bloodstream infection (BSI), particularly those undergoing treatments such as chemotherapy. A common and debilitating side effect of chemotherapy is oral and intestinal mucositis. These Patients are also at high risk of developing sepsis, which can arise from mucosal barrier injuries and significantly increases mortality in these patients.
View Article and Find Full Text PDFBackground: It is thought that patients with inborn errors of immunity (IEI) are more susceptible to severe coronavirus disease 2019 (COVID-19) than the general population, but a quantification of this potential risk is largely missing.
Objective: We assessed the impact of COVID-19 on patients with IEI.
Methods: A nationwide cohort study was performed to estimate the relative risk (RR) for hospitalization, intensive care, and death within 30 days after a positive severe acute respiratory syndrome coronavirus 2 test result in an IEI population (n = 2392) compared to the general population (n = 8,270,705) using data from Swedish national registries.
Can autoantibodies be transferred by immunoglobulin replacement therapy?
Scand J Immunol
November 2024
Article Synopsis
- Immunocompromised patients have shown weak responses to initial SARS-CoV-2 mRNA vaccinations, prompting recommendations for extra booster doses; however, real-world data on these recommendations is limited.
- A two-year follow-up of the COVAXID clinical trial involved 364 participants, focusing on their immune responses and the effects of their vaccination schedule and underlying health conditions.
- The study found that while some patients who initially had poor responses improved after additional doses, their immune response remained affected by their immunosuppressive status, emphasizing the need for ongoing vaccination efforts in these populations.